摘要
目的观察氟达拉滨（fludarabine，Flu）为主方案对我国恶性血液系统肿瘤患者的治疗效果及不良反应。方法2001．03／2005—03我科共采用含Flu为主方案治疗血液系统恶性肿瘤患者15例，男10例，女5例，中位年龄43（15～63）yr。15例中采用FLAG方案（Fiu、Am-C和G-CSF）治疗急性髓系白血病（A^见）3例、急性淋系白血病（ALL）3例；采用舳方案（Flu、米托蒽醌和地塞米松）治疗非霍奇金淋巴瘤（NHL）伴淋巴瘤细胞白血病、脂膜炎样T细胞淋巴瘤及NHL各1例；采用FMD和FC（Flu和CTX）联合方案治疗慢性淋巴细胞白血病（CLL）2例和NHL1例；其余3例分别联合采用FD（Flu和CTX）、FC（Flu、米托葸醌和CTX）以及ED（Flu、CTX和地塞米松）方案治疗。中位治疗周期为2（1，5）个。结果15例患者共采用含FLU的方案治疗30例次，其中28例次治疗有效，元效2例次。4例达到完全缓解（completeremission，CR），7例达到部分缓解（partial remission，PR），2例病情稳定（stable disease，SD），2例疾病进展（progression disease，PD）。骨髓抑制与感染是最主要的不良反应。结论含Flu的化疗方案治疗血液系统恶性肿瘤疗效显著，不良反应较轻，值得进一步深入研究。
Aim To investigate the therapeutic effects and toxicity of fludarabine-based regiments for patients with hematologic malignancies in China. Methods Fifteen patients with hematologic malignancies were enrolled into this study from January 2001 to March 2005. The median therapeutic cycles were 2（range 1 - 5）. Results Of the 30 times, 28 cases responded to the therapy; 2 showed no response to the therapy; 4 achieved complete response （CR）, 7 achieved partial response （PR）, 2 eases had a stable disease （SD） ,2 cases had a progression disease （PD）. Myelosuppression and infection were major side effects. Conclusion These data suggest that fludarabine-based regimens may be an effective therapy for patients with hematologic malignancies, with mild toxicity.So further investigation is wanted.
出处
《世界今日医学杂志》
2005年第4期222-225,共4页
World JOurnal of Medicine Today
